Yulin Qin

Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.

D. Elstein, A. Zimran, D. Gonzalez, 2018, Blood cells, molecules & diseases.

Phase I Study of the Pharmacodynamics and Safety of Sodium Zirconium Cyclosilicate in Healthy Chinese Adults

M. Någård, T. Cheung, June Zhao, 2022, Clinical pharmacology in drug development.

Design, Synthesis and Antifungal Evaluation of Novel Pyrylium Salt In Vitro and In Vivo

Runhui Liu, Quan-Zhen Lv, Jin-Xing Wang, 2022, Molecules.

Development and validation of a sensitive LC-MS/MS method for determination of intracellular concentration of fluconazole in Candida albicans

Yongbing Cao, Yuanying Jiang, Bing Han, 2022, Frontiers in Microbiology.

Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review

Bing Han, Yulin Qin, Jinxin Wang, 2023, Antimicrobial agents and chemotherapy.

Development of anti-velaglucerase alfa antibodies in clinical trial-treated patients with Gaucher disease.

H. Ida, Y. Qiu, G. Pastores, 2016, Blood cells, molecules & diseases.

Results From a 12-Month Open-Label Phase 1/2 Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease:

A. Bavdekar, A. El‐Beshlawy, Iman Marzouk, 2018 .